Biotronik Announces Positive Six-Month Results for DREAMS, the Drug-Eluting Absorbable Metal Scaffold

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the Drug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device. For the first cohort of 22 patients, there was no cardiac death, no target vessel myocardial infarction (MI) and no stent thrombosis, as presented at the European Conference of Paris Course on Revascularization (EuroPCR).
CNBC